8-K: Elicio Therapeutics Reports Progress on Cancer Vaccine Trials, Faces Financial Challenges

Elicio Therapeutics announced progress in its clinical trials for the ELI-002 cancer vaccine, including positive Phase 1 data and the initiation of a Phase 2 trial, while also reporting increased R&D expenses and a net loss for the first quarter of 2024.

Summary

• Elicio Therapeutics reported financial results for Q1 2024 and provided updates on its clinical trials.
• The company highlighted the publication of Phase 1 data for ELI-002 2P in Nature Medicine and the presentation of data at the AACR Annual Meeting.
• Enrollment for the Phase 2 trial of ELI-002 7P has begun, with completion expected by the end of 2024.
• Preliminary data from the Phase 1a trial of ELI-002 7P will be presented at the ASCO Annual Meeting in June 2024.
• Research and development expenses for Q1 2024 were $7.6 million, up from $5.5 million in Q1 2023.
• General and administrative expenses were $2.7 million, compared to $2.3 million in the same period last year.
• The company reported a net loss of $11.8 million for Q1 2024, compared to $8.0 million in Q1 2023.
• As of March 31, 2024, Elicio had $11.9 million in cash and cash equivalents.

Sentiment

Score: 4

Explanation: While the positive clinical data and progress in trials are encouraging, the company's financial situation and the need for additional funding create significant uncertainty and negatively impact the overall sentiment.

Positives

• ELI-002 2P showed promising results in Phase 1, including durable immunogenicity and antigen spreading.
• ELI-002 2P had a favorable safety profile with no significant adverse events.
• The Phase 2 trial of ELI-002 7P is progressing, with enrollment initiated and completion expected in Q4 2024.
• ELI-002 7P has the potential to target a broader patient population due to its coverage of seven common KRAS mutations.
• The company is actively presenting data at major scientific conferences, increasing visibility and potentially attracting collaborations.

Negatives

• The company reported an increased net loss of $11.8 million in Q1 2024 compared to $8.0 million in Q1 2023.
• Cash and cash equivalents decreased to $11.9 million as of March 31, 2024, from $12.9 million at the end of 2023.
• The company's financial condition raises concerns about its ability to continue as a going concern without additional funding.

Risks

• Elicio's financial condition is a significant risk, as it needs additional funding to advance the development of its product candidates.
• The company's ability to continue as a going concern is uncertain.
• Clinical trials may not yield positive results, and product candidates may not receive regulatory approval.
• The company may face challenges in commercializing its products, even if they are approved.
• Competition in the immunotherapy space is intense, and Elicio may face challenges from competitors with greater resources.
• The company's success depends on its ability to protect its intellectual property.
• Changes in government laws and regulations could impact the company's business.

Future Outlook

Elicio Therapeutics expects to complete enrollment in the randomized Phase 2 trial of ELI-002 7P in the fourth quarter of 2024, with interim analysis expected in the first quarter of 2025. They also plan to provide updated immunogenicity and relapse-free survival data from the AMPLIFY-201 trial in the fourth quarter of 2024.

Management Comments

• During the first quarter, we continued to make great progress with our lead program, ELI-002, seeing the first-in-human Phase 1 data on the 2P formulation published in Nature Medicine. We also began enrolling patients with pancreatic cancer in the randomized Phase 2 trial of the 7P formulation, said Robert Connelly, Elicios Chief Executive Officer.
• We look forward to sharing preliminary data from the ELI-002 7P Phase 1 cohort at ASCO while focusing on completing enrollment for the Phase 2 randomized cohort, which is expected by the end of 2024. Robert Connelly, Elicios Chief Executive Officer.
• We have continued to analyze and publish data from our first-in-human study characterizing the robust and differentiated T cell response generated by ELI-002. Building on the magnitude of the KRAS-specific T cell response including both CD4+ and CD8+ recent data presented at AACR, we also demonstrated that ELI-002s mechanism of action includes antigen-spreading, where personal neoantigens are targeted alongside the KRAS-specific response that may enhance clinical activity. Christopher Haqq, M.D., Ph.D., Elicios Executive Vice President, Head of Research and Development, and Chief Medical Officer

Industry Context

This announcement relates to the broader trend of developing immunotherapies for cancer, particularly those targeting specific mutations like KRAS. The field is highly competitive, with many companies pursuing similar approaches. Elicio's focus on lymph node-targeted delivery is a differentiating factor, but the success of this approach remains to be seen.

Comparison to Industry Standards

• Elicio's ELI-002 is an Amphiphile (AMP) cancer vaccine targeting mKRAS-driven cancers, similar to other KRAS-targeting therapies in development by companies like Moderna (mRNA-5671/V941) and Amgen (LUMAKRAS).
• Moderna's mRNA-5671/V941, in combination with KEYTRUDA, has shown promising results in Phase 1 trials for various solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
• Amgen's LUMAKRAS (sotorasib) is an FDA-approved KRAS G12C inhibitor for locally advanced or metastatic NSCLC with a KRAS G12C mutation. It has demonstrated improved progression-free survival compared to chemotherapy in clinical trials.
• BioNTech is also developing KRAS-targeted therapies, including BNT116, an mRNA-based cancer vaccine in Phase 1 trials for advanced solid tumors.
• Elicio's approach of targeting multiple KRAS mutations with ELI-002 7P is similar to other companies developing multi-target or personalized cancer vaccines.
• Compared to these industry standards, Elicio's ELI-002 is still in early-stage development, but the initial Phase 1 data showing durable immunogenicity and antigen spreading is promising.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the need for additional funding, which could lead to dilution.
• Employees may be affected by the company's financial condition and its ability to continue operations.
• Patients with mKRAS-driven cancers could benefit from the successful development of ELI-002, but the timeline for potential approval and commercialization remains uncertain.
• Suppliers and creditors may be impacted by the company's financial condition and its ability to meet its obligations.

Next Steps

• Present preliminary data on ELI-002 7P monotherapy from Phase 1a arm at ASCO in June 2024.
• Complete enrollment in the randomized Phase 2 trial of ELI-002 7P in the fourth quarter of 2024.
• Conduct interim analysis of the Phase 2 AMPLIFY-7P trial in the first quarter of 2025.
• Provide updated immunogenicity and relapse-free survival data from the AMPLIFY-201 trial in the fourth quarter of 2024.

Key Dates

Keywords

cancer vaccine, immunotherapy, KRAS, clinical trials, Phase 1, Phase 2, pancreatic cancer, colorectal cancer, biotechnology, drug development, ASCO, AACR, antigen spreading, CD4+, CD8+, T cell response, Amphiphile, AMP, lymph node, ELI-002, ELI-002 2P, ELI-002 7P, AMPLIFY-201, AMPLIFY-7P